Novo Nordisk raises 2026 outlook as obesity sales jump 22%
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com -- Novo Nordisk raised its full-year 2026 sales and operating profit outlook on Wednesday after stronger-than-expected third-quarter performance, driven by demand for its obesity treatments, although impairment charges pushed reported operating profit lower. Still…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishA guidance raise by a mega-cap drugmaker can move the sector and the broader index.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Novo Nordisk now expects 2026 adjusted sales and operating profit between -2% and +2%.
- 02Previously the range was -6% to 0%.
- 03Obesity care sales rose 22% at constant exchange rates.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets